Skip to content
Review Open access

Causal relationship between liver fat reduction and clinical outcomes in human genetic studies and randomized clinical trials of metabolic-dysfunction associated steatohepatitis

Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

The largest-to-date genome-wide association study of liver fat in 79,642 people with magnetic resonance imaging and developed a polygenic score with liver fat-lowering alleles across 55 genomic loci demonstrate the profound etiologic impact of liver fat in MASH and provide compelling evidence for liver fat reductions as a reasonably likely surrogate endpoint for future clinical development.

Abstract

Reliance on invasive liver biopsy endpoints is a major limiting factor in new therapeutic development for metabolic dysfunction-associated steatohepatitis (MASH). While liver fat accumulation is considered a driver of early disease, liver fat reduction is not recognized as a surrogate endpoint by health authorities. Here, we conducted the largest-to-date genome-wide association study (GWAS) of liver fat in 79,642 people with magnetic resonance imaging and developed a polygenic score with liver fat-lowering alleles across 55 genomic loci. In a separate set of 714,886 individuals, a 30% relative liver fat reduction due to the polygenic score was associated with 39% lower odds of liver cirrhosis and 41% lower odds of hepatocellular carcinoma, consistent with a strong causal relationship between lifelong liver fat differences and advanced liver clinical outcomes. A systematic review and meta-analysis of 20 randomized controlled trials including a total of 3,502 MASH patients showed that treatment-induced liver fat reductions were associated with MASH resolution (meta-regression slope in % units of the outcome for each 1% relative reduction in liver fat from baseline, {beta} = -0.70%, p<0.001) and fibrosis improvement ({beta} = -0.24%, p<0.001). These findings demonstrate the profound etiologic impact of liver fat in MASH and provide compelling evidence for liver fat reductions as a reasonably likely surrogate endpoint for future clinical development.

Read PDF

Similar papers

Open access Oct 2026

Genetic and Body Composition Factors Associated with Metabolic-Associated Steatotic Liver Disease: A Cross-Sectional Analysis of a Health Screening Cohort

Introduction Metabolic-associated steatotic liver disease (MASLD), newly defined in 2023, is characterized by excessive hepatic triglyceride accumulation in the presence of cardiometabolic risk factors. The body roundness index (BRI), an indicator of body fat distribution and visceral adiposity, has been proposed as a...

Yi-Hsuan Shen, Yi-Chen Lee, Tzu-Jung Chou et al. · 0 citations
Review Oct 2026

Serum Uric Acid and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Two-Stage NHANES Study of MASLD Prevalence and All-Cause Mortality.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health challenge, highlighting the need for accessible markers of metabolic liver disease risk. Serum uric acid (SUA) has been linked to metabolic dysfunction, but its association with MASLD across the full clinical spectrum...

Hafiz M. Ahmed, Umm E. Aimen · 0 citations
Oct 2026

Genetic Evidence for the Associations of Alcohol Intake Frequency and Dietary Salt Intake with Non-Alcoholic Fatty Liver Disease Risk and Hepatic Steatosis: A Mendelian Randomization Study.

OBJECTIVE Non-Alcoholic Fatty Liver Disease (NAFLD) poses a significant global health burden, yet causal relationships with modifiable dietary factors remain incompletely defined. This Mendelian Randomization (MR) study evaluated the causal associations between dietary exposures and NAFLD risk, as well as related hepat...

Yong-Xin Ma, Jia-Wei Wang, Zhen-Ya Tan et al. · 0 citations
Open access Oct 2026

Differential Cardiometabolic Risk Profiles of Lean and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease: A Longitudinal Health Checkup Cohort Study.

Lean MASLD shared a broadly similar cardiometabolic risk structure with Obese MASLD, whereas the relative contribution of risk factors differed between phenotypes, providing exploratory evidence of phenotype-specific metabolic associations requiring validation before clinical application.

H. Kawamura, Kei Fujiwara, Ryo Sato et al. · 0 citations
Open access Oct 2026

Exploring the Causal Relationship Between Body Mass Index and Kidney Function: Tissue-Partitioned Mendelian Randomization

Background: Chronic kidney disease (CKD) represents a leading non-communicable disease, significantly contributing to global morbidity and mortality. Mendelian randomization studies (MR) have been integral in providing robust evidence that increased body mass index (BMI) has a causal impact on CKD. However, dissecting...

A. Briasouli, G. Leyden, A. Andries et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.